Switching first-line disease-modifying therapy for relapsing-remitting multiple sclerosis in non-responders: is it a successful strategy?

被引：0
|
作者：
Gajofatto, A. [1 ]
Bacchetti, P. [1 ]
Grimes, B. [1 ]
High, A. [1 ]
Moraes, C. [1 ]
Waubant, E. [1 ]
机构：
[1] Univ Calif San Diego, San Francisco, CA USA
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [31] Relapsing-remitting multiple sclerosis and oligoclonal band pattern during disease-modifying drug therapy
    Mares, J
    Herzig, R
    Urbanek, K
    Bekarek, V
    Sklenarova, J
    Zapletalova, J
    Hlustik, P
    Kanovsky, P
    NEUROLOGY, 2006, 66 (05) : A371 - A371
  • [32] Impact of switching first-line diseasemodifying therapy (DIVIT) after failure in relapsing-remitting multiple sclerosis (RRMS)
    Gajofatto, A.
    Waubant, E.
    High, A.
    MULTIPLE SCLEROSIS, 2007, 13 (09): : 1224 - 1224
  • [33] Oral drugs versus interferon-beta or glatiramer acetate as first-line disease modifying therapy in relapsing-remitting multiple sclerosis
    Benkert, P.
    Lienert, C.
    Lorscheider, J.
    Hanni, P.
    Decard, B.
    Kuhle, J.
    Derfuss, T.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 684 - 684
  • [34] COST-EFFECTIVENESS OF FIRST-LINE DISEASE-MODIFYING THERAPIES (DMTs) FOR RELAPSING-REMITTING MS (RAMS)
    Soini, E. J.
    Joutseno, J.
    Somelahti, M.
    VALUE IN HEALTH, 2015, 18 (07) : A756 - A756
  • [35] Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes
    Yano, Hajime
    Gonzalez, Cindy
    Healy, Brian C.
    Glanz, Bonnie, I
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 35 : 119 - 127
  • [36] An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM)
    Schmidt, Stephan
    Koehler, Juergen
    Winterstein, Christine
    Schicklmaier, Petra
    Kallmann, Boris
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [37] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
  • [38] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [39] Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis
    Calabrese, M.
    Bernardi, V.
    Atzori, M.
    Mattisi, I.
    Favaretto, A.
    Rinaldi, F.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 418 - 424
  • [40] Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
    Abdel-mannan, Omar A.
    Manchoon, Celeste
    Rossor, Thomas
    Southin, Justine-Clair
    Tur, Carmen
    Brownlee, Wallace
    Byrne, Susan
    Chitre, Manali
    Coles, Alasdair
    Forsyth, Rob
    Kneen, Rachel
    Mankad, Kshitij
    Ram, Dipak
    West, Siobhan
    Wright, Sukhvir
    Wassmer, Evangeline
    Lim, Ming
    Ciccarelli, Olga
    Hemingway, Cheryl
    Hacohen, Yael
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (04):
12345